CN102093234B - Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof - Google Patents
Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof Download PDFInfo
- Publication number
- CN102093234B CN102093234B CN201010571246.6A CN201010571246A CN102093234B CN 102093234 B CN102093234 B CN 102093234B CN 201010571246 A CN201010571246 A CN 201010571246A CN 102093234 B CN102093234 B CN 102093234B
- Authority
- CN
- China
- Prior art keywords
- compound
- trometamol
- preparation
- solvent
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- -1 Tromethamine salt compound Chemical class 0.000 title abstract description 22
- 239000002253 acid Substances 0.000 title abstract description 6
- QYMFNZIUDRQRSA-UHFFFAOYSA-N dimethyl butanedioate;dimethyl hexanedioate;dimethyl pentanedioate Chemical compound COC(=O)CCC(=O)OC.COC(=O)CCCC(=O)OC.COC(=O)CCCCC(=O)OC QYMFNZIUDRQRSA-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 234
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 108
- 229960000281 trometamol Drugs 0.000 claims description 94
- 239000002904 solvent Substances 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- 208000029028 brain injury Diseases 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000007924 injection Substances 0.000 abstract description 43
- 238000002347 injection Methods 0.000 abstract description 43
- 239000012453 solvate Substances 0.000 abstract description 32
- 150000003839 salts Chemical class 0.000 abstract description 10
- 230000000638 stimulation Effects 0.000 abstract description 6
- 230000003387 muscular Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical compound CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- 239000000843 powder Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010047228 Venous injury Diseases 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000007919 dispersible tablet Substances 0.000 description 4
- 239000007938 effervescent tablet Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000002662 enteric coated tablet Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229940100688 oral solution Drugs 0.000 description 4
- 239000006191 orally-disintegrating tablet Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003016 phosphoric acids Chemical class 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000004691 decahydrates Chemical class 0.000 description 2
- 238000004455 differential thermal analysis Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 150000004688 heptahydrates Chemical class 0.000 description 2
- 150000004687 hexahydrates Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 150000004690 nonahydrates Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000004686 pentahydrates Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000004685 tetrahydrates Chemical class 0.000 description 2
- 150000004684 trihydrates Chemical class 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Abstract
The invention relates to a tromethamine salt compound of a derivative (compound D) of dibasic ester acid, which comprises diamido-butantriol, monoamino-butantriol, a hydrate or a solvate of the tromethamine salt compound. The tromethamine salt compound has good water solubility and stability and improves untoward effects such as muscular stimulation, muscle stimulation, and the like of the metal salt of the compound while injection. The invention also provides a preparation method and medicinal application of the tromethamine salt compound.
Description
Technical field the invention belongs to pharmaceutical technology field, relates to a kind of derivative salt compound of dibasic ester acid, and concrete is its Trometamol salt compound, and preparation method thereof the application in medicine with them.
Background technology DP-BAPTA-99 is new compound, is a kind of compound of dibasic ester acid structure, in present specification, is called " Compound D ", and its molecular structural formula is as follows:
The open WO99/16741 of international application discloses the chemical structural formula of Compound D.
Compound D, as a kind of nerve protection medicine of new acute apoplexy, has been applied to clinical study.But disadvantageously, on the one hand, Compound D water-soluble very poor, is insoluble in water, is unfavorable for the preparation of pharmaceutical preparation and is not easy to stripping in pharmaceutical preparation; On the other hand, metal ion type salt has short Decomposition for two ester group structures in Compound D structure, is unfavorable for stability and the application of medicine; Again on the one hand, the metal-salts such as the disodium salt of Compound D, in the time that injection is used, tend to cause the stronger untoward reaction such as vascular stimulation, muscular irritation.
Common, make target compound form salt formula compound, be the top-priority method of improving target compound.For the application of pharmaceutical preparation production aspect, usually advantageously adopt the pharmaceutical active compounds of the specific salts form that contains acidic group or base, they for example have better solvability, better stripping and absorption behavior, better stability or common better properties curve, use specific salts, also can be favourable to the preparation of active compound or pharmaceutical preparation, or to meet medicine regulatory authority require favourable, for example, be conducive to the clinical application of medicine, improve the compliance of patient's medication, be conducive to the result for the treatment of of medicine.
Summary of the invention, under the prerequisite of pharmacological action that does not change Compound D, improves water-soluble, the stability of Compound D, and the untoward reaction such as vascular stimulation, muscular irritation while improving injection use, is very important and significant.Contriver is through experiment discovery, and the non-metal salt of Compound D can improve the weak point of Compound D or its metal-salt.
In Compound D molecular structure, contain two carboxyls, contriver finds through experiment, adopts water-soluble good alkaline matter----Trometamol, with the carboxylic group coordination salify of Compound D, can significantly improve the water-soluble of Compound D.But, in the time considering to improve water-soluble, also to consider the pharmacological action that can not change and destroy Compound D, and with it the alkaline coordination material of salify not only basicity is suitable, and nontoxic to human-body safety, also to consider that institute's salt-forming compound should have satisfactory stability and physical appearance, is applied to pharmaceutical preparation using the derivative salt that is convenient to Compound D as active constituents of medicine.Further, to there is good promoter action for the stability of Compound D; In addition, the untoward reaction such as blood vessel pain, muscular irritation can improve its injection use time.
Trometamol, has another name called three (methylol) aminomethane, and chemistry is by name: TRIS, molecular formula C
4h
11nO
3, Trometamol belongs to alkaline matter, and good stability is nonhygroscopic, high to human safety, and injection or oral equal safety non-toxic use as auxiliary material in multi-medicament prescription.
Based on above consideration and requirement, the inventor by experiment and screening, completed the compounds of this invention D tromethamine salt, it comprises Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate.
Further, the invention provides the preparation method of Compound D tromethamine salt; The present invention also provides the medicinal application of Compound D tromethamine salt.
The invention provides the compound shown in formula I, its hydrate or its solvate:
Compound D one Trometamol:
Compound D two Trometamols:
Concrete, the salt compound of Compound D provided by the invention and Trometamol, it comprises Compound D one Trometamol, Compound D two Trometamols, with and hydrate or its solvate.
Should illustrate, and those skilled in the art should be familiar with and understand, due to the external neutral of compound of institute of the present invention salify or electrically not aobvious, therefore, the compound of institute of the present invention salify can also represent by the chemical structure of following general formula I I-1 or general formula III-1:
Should illustrate, and those skilled in the art should be familiar with and understand, in compound due to institute of the present invention salify, with the molecule number of the Trometamol of a part Compound D coordination salify be 1 or 2, in the expression of molecular structure, by the molecular digital of Trometamol be marked on Trometamol molecular formula above with the suffix that is marked on Trometamol molecular formula, be all the same, for example, the compound of institute of the present invention salify can also represent by the chemical structure of following general formula I I-2 or general formula III-2:
Molecular formula C
42h
64n
2o
12.C
4h
11nO
3,
Molecular formula C
42h
64n
2o
12. (C
4h
11nO
3)
2.
What formula II-1, formula II-2 and formula II represented is same compound, i.e. Compound D one Trometamol;
What formula III-1, formula III-2 and formula III represented is same compound, i.e. Compound D two Trometamols.
The Trometamol salt compound of the compounds of this invention D is a kind of solid chemical compound, there is good physical appearance, in preparation process, for keeping peculiar structural form, may contain a certain amount of water molecules or solvent molecule, therefore, the present invention also comprises hydrate or the solvate of above-claimed cpd D Trometamol.
For example, the semihydrate of Compound D two Trometamols of the present invention, monohydrate, sesqui hydrate, dihydrate, two times of semihydrates, trihydrate, three times of semihydrates, tetrahydrate, four times of semihydrates, pentahydrate, five times of semihydrates, hexahydrate, six times of semihydrates, heptahydrate, seven times of semihydrates, eight hydrates, octuple semihydrate, nonahydrate, nine times of semihydrates or decahydrate, etc.;
For example, the semihydrate of Compound D one Trometamol of the present invention, monohydrate, sesqui hydrate, dihydrate, two times of semihydrates, trihydrate, three times of semihydrates, tetrahydrate, four times of semihydrates, pentahydrate, five times of semihydrates, hexahydrate, six times of semihydrates, heptahydrate, seven times of semihydrates, eight hydrates, octuple semihydrate, nonahydrate, nine times of semihydrates or decahydrate, etc.
Again for example, the solvent molecule that Compound D two Trometamols of the present invention contain half molecule, 1 molecule, 1.5 molecules, 2 molecules, 2.5 molecules, 3 molecules, 3.5 molecules, 4 molecules, 4.5 molecules, 5 molecules, 5.5 molecules, 6 molecules, 6.5 molecules, 7 molecules, 7.5 molecules, 8 molecules, 8.5 molecules, 9 molecules, 9.5 molecules or 10 molecules, etc.;
Again for example, the solvent molecule that Compound D one Trometamol of the present invention contains half molecule, 1 molecule, 1.5 molecules, 2 molecules, 2.5 molecules, 3 molecules, 3.5 molecules, 4 molecules, 4.5 molecules, 5 molecules, 5.5 molecules, 6 molecules, 6.5 molecules, 7 molecules, 7.5 molecules, 8 molecules, 8.5 molecules, 9 molecules, 9.5 molecules or 10 molecules, etc.
Should illustrate, above-mentioned many compounds of this invention D bis-Trometamols of enumerating or hydrate or the solvate of Compound D one Trometamol, just the compounds of this invention D Trometamol contingent situation in crystallization or purge process, any hydrate or solvate in them, it is only the existence form of the compounds of this invention D derivative material, contained crystal water or recrystallisation solvent normally can be controlled or remove, for example by adding thermal burn or turning crystalline substance, crystal water or recrystallisation solvent are removed, therefore, the hydrate of above-mentioned many Compound D derivatives of enumerating or solvate still belong to the content of technical scheme content of the present invention and scope of patent protection.
The present invention also provides the preparation method of Compound D Trometamol, its hydrate or its solvate, it is included in solvent Compound D is contacted with Trometamol, reaction salify, described solvent is selected from the mixing of one or more solvents in ethanol, methyl alcohol, Virahol, acetone, acetonitrile, ethyl acetate, water, N,N-DIMETHYLACETAMIDE, dimethyl formamide; Described temperature of reaction be in room temperature to the reflux temperature condition of solvent, make Compound D react salify with Trometamol.
In embodiments of the invention scheme, described Compound D Trometamol, its hydrate or solvate is as described in the unrestricted embodiment of compound of the present invention, in information as herein described, by with such as described similar method, in the solution that contains Compound D, add Trometamol, or add Compound D in the solution that contains Trometamol, or the solution that contains Compound D is mixed with the solution that contains Trometamol, to reach, Compound D is contacted to the object of reaction salify with Trometamol.
For the preparation of Compound D one Trometamol, its hydrate or solvate, concrete,
In room temperature to the reflux temperature condition of solvent, be 1 by mol ratio: the Compound D of (1～1.1) contacts in solvent with Trometamol, reaction salify, and under room temperature or the condition lower than room temperature, make institute's salify crystallization, filter, after washing, drain, dry, obtain Compound D one Trometamol, or its hydrate, solvate, wherein said solvent is selected from ethanol, methyl alcohol, Virahol, acetone, acetonitrile, ethyl acetate, water, N,N-DIMETHYLACETAMIDE, the mixing of one or more solvents in dimethyl formamide, optionally can be by reducing Tc or/and steam except partial solvent is to accelerate the formation of crystallization, or,
The Compound D that is 1: 1 by mol ratio and Trometamol make them dissolve completely in 5～80 DEG C in suitable quantity of water, stir, and lyophilize, obtains Compound D one Trometamol or its hydrate.
For the preparation of Compound D two Trometamols, its hydrate or solvate, concrete,
In room temperature to the reflux temperature condition of solvent, be 1 by mol ratio: the Compound D of (2～2.2) contacts in solvent with Trometamol, reaction salify, and under room temperature or the condition lower than room temperature, make institute's salify crystallization, filter, after washing, drain, dry, obtain Compound D two Trometamols, or its hydrate, solvate, wherein said solvent is selected from ethanol, methyl alcohol, Virahol, acetone, acetonitrile, ethyl acetate, water, N,N-DIMETHYLACETAMIDE, the mixing of one or more solvents in dimethyl formamide, optionally can be by reducing Tc or/and steam except partial solvent is to accelerate the formation of crystallization, or,
The Compound D that is 1: 2 by mol ratio and Trometamol make them dissolve completely in 5～80 DEG C in suitable quantity of water, stir, and lyophilize, obtains Compound D two Trometamols or its hydrate.
For Compound D, can be synthetic according to following operational path, be mainly calcium sequestrant BAPTA (two (adjacent amino-benzene) ethane-N of chemical name: 1,2-, N, N ', N '-tetra-acetyl acid) and bromooctane with raw material:
For Trometamol, conventionally can commercially obtain.
Further, the invention provides the pharmaceutical composition that contains Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate and pharmaceutically acceptable carrier.
Can pass through the administration Compound D tromethamine salt of the present invention of any appropriate, but conventionally by parenterai administration or oral administration, be preferably injection system.In order to carry out this class application, generally use the salt of Compound D of the present invention with the pharmaceutical compositions that contains pharmaceutically acceptable carrier, but, the exact form of said composition depends on form of medication naturally.
Concrete, the present invention also provides one to contain Compound D two Trometamols of the present invention, Compound D one Trometamol, the pharmaceutical composition of its hydrate or its solvate, and contain one or more pharmaceutically acceptable carrier, wherein Compound D two Trometamols, Compound D one Trometamol, the content of its hydrate or its solvate is 0.1～500mg, for example 0.1mg, 0.2mg, 0.5mg, 0.7mg, 1mg, 2mg, 3mg, 4mg, 5mg, 7mg, 10mg, 15mg, 20mg, 25mg, 30mg, 40mg, 41mg, 42mg, 43mg, 45mg, 47mg, 48.5mg, 50mg, 60mg, 62mg, 70mg, 80mg, 82mg, 83mg, 85mg, 88mg, 90mg, 92mg, 95mg, 98mg, 100mg, 110mg, 116mg, 120mg, 125mg, 130mg, 132mg, 135mg, 140mg, 150mg, 166mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg.
Taking the compounds of this invention D bis-Trometamols, Compound D one Trometamol, its hydrate or its solvate as active ingredient, and contain one or more pharmaceutically acceptable pharmaceutical carriers, be mixed with the form through any suitable administration, can prepare any pharmaceutical dosage form of acceptable in pharmaceutics, comprise injection formulations, oral preparations, parenteral liquid preparation, etc., as injection, comprise powder ampoule agent for injection and injection liquid, etc.; And for example oral tablet, capsule, granule, oral solution, powder agent, pill, sublingual administration agent etc.; For another example the emulsion of parenteral eye drop, nasal drops, [Dan, Transdermal absorption, etc.Also can be the formulations such as the quick-release, slowly-releasing, controlled release of above various formulations, for example oral dispersible tablet, slow releasing tablet, chewable tablet, slow releasing capsule, enteric coated tablet, effervescent tablet, orally disintegrating tablet, special-shaped tablets, effervescent granule, etc.Especially, by means known in the art preparation, be preferred for preparing the tablet (comprising dispersible tablet, slow releasing tablet, chewable tablet, enteric coated tablet, effervescent tablet, orally disintegrating tablet, special-shaped tablets) that uses in pharmaceutics, capsule (comprise that stomach is molten, enteric, slow releasing capsule), granule, oral solution, injection (comprising powder ampoule agent for injection and injection liquid) etc., to meet the various needs in clinical use.
Be to be understood that, according to method well known in the art, pharmaceutical carrier is matrix or the auxiliary material that keeps pharmaceutical dosage form, conventionally select or be used in combination according to different medicaments, optionally comprise vehicle or thinner, for example, in Microcrystalline Cellulose, lactose, pregelatinized Starch, starch, dextrin, calcium phosphate, sucrose, dextran, N.F,USP MANNITOL, sorbyl alcohol, glucose, fructose, water, polyoxyethylene glycol, propylene glycol, glycerine, cyclodextrin, cyclodextrin derivative one or more, etc.; Also can comprise tackiness agent, for example, in polyvidone (polyvinylpyrrolidone), methylcellulose gum, Walocel MT 20.000PV, HPMC, hydroxypropylcellulose, Natvosol, gelatin, guar gum, xanthan gum one or more, etc.; Also comprise lubricant, for example, in Magnesium Stearate, stearic acid, talcum powder, stearyl fumarate, Sodium Lauryl Sulphate BP/USP one or more, etc.; Also can comprise disintegrating agent, for example, in sodium starch glycolate, low-substituted hydroxypropyl cellulose, Xylo-Mucine, cross-linked polyvinylpyrrolidone, croscarmellose sodium, crosslinked carboxymethyl fecula sodium, pregelatinized Starch one or more, etc.; Also comprise tensio-active agent, for example, in sodium lauryl sulphate, Tween-80 one or more, etc.; Also can comprise pH value conditioning agent or buffer reagent, one or more of for example phosphate buffered saline buffer, citric acid, Trisodium Citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide, etc.; Also can comprise sanitas, for example, in Sodium Benzoate, potassium sorbate, methyl p-hydroxybenzoate, propylparaben one or more, etc.; Also can comprise stablizer and oxidation inhibitor, for example, in Calcium Disodium Edetate, S-WAT, vitamins C one or more, etc.; Also can comprise taste conditioning agent, for example, in maltose alcohol, fructose, sucrose, soluble saccharin, flavoring orange essence, strawberry flavour one or more, etc.; Also can comprise in addition additive other routine, appropriate.
Should be appreciated that above-mentioned " optionally comprising " both referred to also can not use optionally choice for use.
It is also understood that when agent type is tablet or capsule, can be film dressing.For the material of film dressing, comprise applicable Drug coating, for example HPMC, Natvosol, hydroxypropylcellulose, hydroxypropyl methylcellulose phthalate, etc.; Also can comprise softening agent, for example polyoxyethylene glycol, triethyl citrate, etc.; Also comprise suitable solubilizing agent, as Polyoxyethylene Sorbitan Monooleate; Also can comprise suitable pigment, as titanium dioxide, various ferric oxide, pink pigment, etc.
Pharmaceutical composition as above, contain one or more pharmaceutically acceptable pharmaceutical carriers, be mixed with the form through any suitable administration, can prepare any pharmaceutical dosage form of acceptable in pharmaceutics, Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate are active substances wherein, in pharmaceutical composition, can also comprise other and have the material of pharmaceutical active, form a kind of pharmaceutical composition of compound, carry out combination therapy.
Further, the preparation method of pharmaceutical composition of the present invention, the method comprises Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate and pharmaceutically acceptable carrier are fully mixed and made into acceptable any pharmaceutical dosage form in pharmaceutics, preferred pharmaceutical dosage form is injection (comprising powder ampoule agent for injection and injection liquid), tablet (comprises dispersible tablet, slow releasing tablet, enteric coated tablet, effervescent tablet, orally disintegrating tablet, special-shaped tablets etc.), capsule (comprises that stomach is molten, enteric, slow releasing capsule), granule, oral solution etc.
Concrete, the preparation method of pharmaceutical composition as above, the method comprises Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate and pharmaceutically acceptable pharmaceutical carrier are fully mixed and made into acceptable any pharmaceutical dosage form in pharmaceutics, preferred pharmaceutical dosage form is injection (comprising powder ampoule agent for injection and injection liquid), tablet (comprises dispersible tablet, slow releasing tablet, enteric coated tablet, effervescent tablet, orally disintegrating tablet, special-shaped tablets etc.), capsule (comprises that stomach is molten, enteric, slow releasing capsule), granule, oral solution, parenteral liquid preparation, for example parenteral eye drop, nasal drops, [Dan, the emulsion of Transdermal absorption, cutaneous permeable agent (comprises the emulsifiable paste of Transdermal absorption, gel, emulsion, emulsion agent, patch etc.), Deng.
In addition, the pharmaceutical composition of salt of the present invention, can form pharmaceutical composition by mixing cpd, and particularly, composition of the present invention can comprise Compound D and the Trometamol of structural formula below by mixing:
Be to be understood that, mixing cpd D and Trometamol, can be to carry out in solvent, for example in the environment that has water, carry out, as: preferably in purified water (as deionized water or distilled water) or/and mix in ethanol, dissolve, further adopt dry, Rotary Evaporators is dry, drying under reduced pressure or vacuum-drying, cryodesiccated method obtain pharmaceutical composition; Also can be that the pressed powder of Compound D and the pressed powder of Trometamol mix, for example, adopt the preparation method of solid dispersion to be obtained by mixing pharmaceutical composition.
The invention still further relates to Compound D two Trometamols, Compound D one Trometamol, its hydrate or the application in the following areas of its solvate:
Application in preparation treatment Acute ischemic stroke medicine;
Application in the brain injury causing in preparation treatment cardiac operation under direct vision and the medicine of traumatic brain injury;
Application in the medicine of preparation treatment DPN disease;
Application in the medicine of preparation treatment Parkinson's disease and alzheimer's disease.
Brief description of the drawings: relevant accompanying drawing provided by the invention is as follows:
Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of Compound D
1h NMR (DMSO-d
6);
Fig. 2 is the carbon-13 nmr spectra figure of Compound D
13c NMR (DMSO-d
6).
The advantage of the compounds of this invention D derivative salt:
1. the compounds of this invention D bis-Trometamols, Compound D one Trometamol, its hydrate or its solvate, its alkaline ligand is safe and reliable, human body is not had to extra side effect, and the stable in properties of the compounds of this invention D bis-Trometamols, Compound D one Trometamol, its hydrate or its solvate, be difficult for decomposing, be easy to preserve and use as bulk drug.
Stability test:
Compound D at high temperature can be decomposed conventionally, generates its monoesters analogue and other impurity, is referred to as total related substance, under hot conditions, measures the wherein content of total related substance, analyzes its stability.
Get respectively appropriate Compound D two Trometamols, Compound D one Trometamol, Compound D disodium, put in weighing bottle and be positioned in 50 DEG C of baking ovens, respectively at sampling in the 5th, 10 days, measure total related substance wherein.
Adopt high-efficient liquid phase chromatogram technique analysis, test-results is in table 1.
Table 1
Measurement result shows, 50 DEG C of Compound D two Trometamols, Compound D one Trometamol, Compound D disodium high temperature are placed 10 days, total its related substances increases to some extent, total its related substances of Compound D disodium is far longer than the content of total related substance of Compound D two Trometamols, Compound D one Trometamol, total related substance percentage composition net added value the 10th day time, Compound D disodium is the more than 1.5 times of Compound D one Trometamol, is that Compound D two Trometamols are more than 1.9 times.Can find out, the stability of Compound D two Trometamols, Compound D one Trometamol significantly improves than Compound D disodium.
2. the compounds of this invention D bis-Trometamols, Compound D one Trometamol, its hydrate or its solvate is water-soluble good, has improved the water-soluble of Compound D.
Through rough determination comparison, Compound D two Trometamols, Compound D one Trometamol, Compound D water dissolution characteristic (normal temperature and pressure) are compared as follows table 2.
Table 2
As can be seen from Table 1, the compounds of this invention D bis-Trometamols, the water-soluble Compound D that is far longer than of Compound D one Trometamol, show the water-soluble of its excellence.
The compounds of this invention D bis-Trometamols, Compound D one Trometamol, its hydrate or its solvate excellence water-soluble for Compound D, the stripping in preparation has good promoter action.Especially for oral preparations, significant.
Be to be understood that, oral medicament need to just can enter blood of human body to reach therapeutic action through GI absorption, and the quality of oral absorption directly affects the result for the treatment of of medicine.According to the concept of pharmaceutics, bioavailability (Bioavailability) refers to that medicine is absorbed to enter and sanguimotorly utilizes degree and utilize speed.Compare Compound D, the compounds of this invention D tromethamine salt has excellent water-soluble, enters aspect sanguimotor degree and speed in absorption for the oral drug preparation taking it as active ingredient, has important promoter action and meaning.Medicament enters the absorption process after stomach and intestine, divide two stages, it is two stages of disintegration dispersion and Gastrointestinal Wall Absorption, first need in gastric juice or intestinal juice, disintegration scatter, and then contact and be attached to gastrointestinal wall and absorb and enter blood, this two stages all can affect absorbing and the performance of drug effect of medicine, Compound D is prepared as to water-soluble good derivative form, drug-eluting speed is significantly accelerated, degree and the rate of dispersion of its disintegration dispersion in gastric juice or intestinal juice are greatly improved, medicament active composition is more abundant with contacting of gastrointestinal wall, be attached to Gastrointestinal Wall Absorption and to enter the active ingredient of blood also more abundant, this raising for the bioavailability of efficacy component Compound D tromethamine salt is significant.
4. the compounds of this invention D bis-Trometamols, Compound D one Trometamol, its hydrate or its solvate, in the time that injection is used, have improved the untoward reaction such as vascular stimulation, muscular irritation, are significantly better than Compound D disodium, sylvite.
Vascular stimulation tests:
Get 32 of rabbit, weight 1.8～2.2kg, male and female half and half, be divided at random four groups, it is Compound D one Trometamol injection liquid group (physiological saline solution, phosphoric acid salt is adjusted PH=7 ± 0.5, 1mg/ml), Compound D two Trometamol injection liquid group (physiological saline solutions, phosphoric acid salt is adjusted PH=7 ± 0.5, 1mg/ml), Compound D two sodium injection group (physiological saline solutions, phosphoric acid salt is adjusted PH=7 ± 0.5, 1mg/ml) with normal saline solution group, every group 8, shave off the rabbit hair that covers auricular vein with stainless steel blade, the left ear of alcohol disinfecting rabbit,
The 1st group of auricular vein injection Compound D one Trometamol injection liquid 1.1mg/kg, 1 time/d;
The 2nd group of auricular vein injection Compound D two Trometamol injection liquid 1.24mg/kg, 1 time/d;
The 3rd group of auricular vein injection Compound D two sodium injection 1.0mg/kg, 1 time/d;
The 4th group of auricular vein injecting normal saline injection liquid 1.0ml/kg, 1 time/d;
Injection speed is 2.0ml/min, injects continuously 14d, and all inject at same position every day, observes animal systemic reaction and injection site every day and has or not the congestion of blood vessel and oedema reaction, puts to death in the 14th day, draws materials and makes pathologic finding.
Inflammatory response deciding degree vein inflammatory level of response judging criterion: under light microscopic, be divided into 4 grades according to Inflammatory response degree,
NIP reaction (-): rarely seen vein is reticular tissue congestion and edema around;
Mild inflammation (+): blood vessel around reticular tissue is shown in lymphocyte, plasmocyte infiltrating, and vessel wall and lumen of vessels have no inflammatory cell;
Moderate inflammation (++): blood vessel around each layer of reticular tissue and vessel wall has lymphocyte, plasmocyte and a little neutrophil infiltration;
Hyperphlogosis (+++): blood vessel is reticular tissue, each layer of vessel wall and the visible diffusivity lymphocyte of lumen of vessels, neutrophil infiltration around, the visible more exudate of Endovascular and downright bad cell debris.
Each group rabbit Inflammatory response situation the results are shown in Table 3.
Table 3
Result is visible, normal saline solution group does not have venous injury substantially, Compound D two Trometamol injection liquid groups have the slight venous injury of 3 example, Compound D one Trometamol injection liquid group has the slight venous injury of 4 example, there is no moderate to hyperphlogosis, and Compound D two sodium injection group venous injury are serious, only 1 routine mild inflammation, all the other are moderate to hyperphlogosis, show that Compound D Trometamol saline injection group and Compound D two sodium injection group comparing differences have statistical significance (P < 0.01).
Embodiment is in implementation process of the present invention, those of ordinary skill in the art do not depart from the scope of the present invention with the basis of spirit on the various embodiments that produce and modify apparent and be easily to carry out, the invention is not restricted to the scope of specific embodiment as herein described, really, various modification of the present invention, except those that narrated are to be understood by those skilled in the art from narration above.Carry out the derivative salt compound to the compounds of this invention D by the following examples, and preparation method thereof should be used as further in medicine illustrates with it, but do not represent embodiment limitation of the present invention.
In embodiments of the invention scheme, the derivative salt compound of following Compound D is as described in the unrestricted embodiment of compound of the present invention, in information as herein described, by with described similar method below, in Compound D, add the Trometamol of needs, or in the solution that contains Trometamol, add the Compound D of needs, or the solution that contains Compound D is mixed with the solution that contains Trometamol, to reach, Compound D is contacted to the object of reaction salify with Trometamol.
First, for Compound D, can be synthetic according to operational path of the present invention, the proton nmr spectra of Compound D and carbon-13 nmr spectra data are as follows:
1HNMR(DMSO-d
6)δ(ppm)：0.834～0.860(6H，t)，1.231(20H，d)，1.420～1.444(4H，m)，3.294～3.411(8H，m)，3.988～4.205(16H，m)，6.724～6.955(8H，m)。
13CNMR(DMSO-d
6)δ(ppm)：13.965，22.086，25.581，28.679，28.832，29.107，31.259，53.068，53.251，63.263，67.093，67.643，70.222，113.901，118.159，121.135，139.068，149.614，170.935，172.171。
In mass spectroscopy: ESI-MS (m/z), quasi-molecular ion peak [M+1] is 790.4, with C in its molecular formula
42h
64n
2o
12conform to.
Embodiment 1. Compound D two Trometamols and preparations thereof
Getting 1g (1.267mmol) Compound D adds in 90ml Virahol, stir and heat and make to dissolve completely, add the solution of 0.31g (2.54mmol) Trometamol in 190ml Virahol, slowly add and stir, more than finishing rear insulated and stirred 30min, be down to room temperature, optionally can be with steaming at 35 DEG C of Rotary Evaporators except partial solvent, put in refrigerator cooling, make its sufficient crystallising, suction filtration, 6ml cold isopropanol washing for filter cake, vacuum-drying, to constant weight powder, obtains Compound D two Trometamols.
1HNMR(DMSO-d
6)δ(ppm)：0.833～0.855(6H，t)，1.227(23H，s)，1.431(4H，s)，3.302(4H，m)，3.418(4H，d)，3.630(4H，s)，3.912(4H，s)，4.168(8H，d)，5.801(10H，broad s)，6.785(6H，s)，6.887(2H，d)。
13CNMR(DMSO-d
6)δ(ppm)：13.982，22.147，25.627，28.756，28.908，29.168，31.320，53.495，55.556，60.104，60.271，63.141，66.926，67.719，70.314，113.383，118.190，120.266，121.029，140.442，149.431，171.789，174.888。
Embodiment 2. Compound D two Trometamols and preparations thereof
Get 1g (1.267mmol) Compound D and add in 55ml ethanol, stir and heat and make to dissolve completely, add the solution of 0.31g (2.54mmol) Trometamol in 60ml ethanol, slowly add and stir, more than finishing rear insulated and stirred 30min, be down to room temperature, optionally can steam except partial solvent with Rotary Evaporators, put in refrigerator cooling, make its sufficient crystallising, suction filtration, the cold ethanol of 5ml or washing with acetone for filter cake, vacuum-drying, to constant weight, obtains Compound D two Trometamols.
Compound D two Trometamols of above-mentioned preparation or its hydrate, through proton nmr spectra, carbon spectrum analysis, are all consistent with embodiment 1.
Embodiment 3. Compound D two Trometamols or its hydrate and preparations thereof
Getting 1g (1.267mmol) Compound D adds the stirring of 20ml distilled water to obtain suspension, the solution of the Trometamol that adds 2.534mmol under stirring in 8ml distilled water, slowly adds and stirs, and finishes more than 30～45 DEG C of rear insulations stir 10min, make to form clear and bright solution, be down to room temperature, by cryodesiccated common process, send into that in the freeze drying box of having sterilized, to carry out freeze-drying dry, pre-freeze 5 hours, temperature drops to-35 DEG C, distils for the first time 8 hours, and temperature rise is to-5 DEG C; Distil for the second time 7 hours, temperature rise to 25 DEG C, vacuum-drying, to constant weight, to obtain final product, and through proton nmr spectra, carbon-13 nmr spectra, differential thermal analysis TG-DTA collection of illustrative plates, shows that products therefrom is Compound D two Trometamols and hydrate thereof.
Optionally, by above-mentioned Compound D two Trometamols and the further recrystallization of hydrate thereof, with purifying, the solvent of recrystallization can be selected acetone-water mixing solutions, alcohol-water mixing solutions, methanol-water mixing solutions or ether-water mixed solution.
Compound D two Trometamols of above-mentioned preparation or its hydrate, through proton nmr spectra, carbon spectrum analysis, are all consistent with embodiment 1.
Embodiment 4. Compound D one Trometamol and preparations thereof
Getting 1g (1.267mmol) Compound D adds in 60ml methyl alcohol, stir and be heated to 50 DEG C and make to dissolve completely, add the solution of 0.153g (1.267mmol) Trometamol in 25ml methyl alcohol, slowly add and stir, more than finishing rear insulated and stirred 30min, be down to room temperature, optionally can steam except partial solvent with Rotary Evaporators, put in refrigerator cooling, make its sufficient crystallising, suction filtration, 4ml cold methanol washing for filter cake, vacuum-drying, to constant weight, obtains Compound D one tromethamine salt.
1HNMR(DMSO-d
6)δ(ppm)：0.833～0.856(6H，t)，1.226～1.271(22H，m)，1.418～1.440(4H，m)，3.293～3.305(4H，m)，3.365～3.402(2H，m)，3.641(4H，s)，3.993(8H，d)，4.132(4H，s)，4.201(2H，s)，5.813(7H，broad s)，6.720～6.734(6H，m)，6.813～6.843(4H，m)，6.934～6.950(2H，m)。
13CNMR(DMSO-d
6)δ(ppm)：13.952，22.139，25.630，28.761，28.898，29.172，31.331，39.637，53.513，55.564，60.088，60.293，63.148，67.011，67.722，70.350，113.401，118.121，120.358，121.156，140.389，149.437，171.793，172.251，175.103。
Embodiment 5. Compound D one Trometamol or its hydrate and preparations thereof
Getting 1g (1.267mmol) Compound D adds the stirring of 20ml distilled water to obtain suspension, the Trometamol aqueous solution that adds 1.267mmol under stirring, slowly adds and stirs, more than finishing 30～45 DEG C of stirring 10min of rear insulation, make to form clear and bright solution, be down to room temperature, by cryodesiccated common process, send into that in the freeze drying box of having sterilized, to carry out freeze-drying dry, pre-freeze 5 hours, temperature drops to-35 DEG C, distils for the first time 8 hours, and temperature rise is to-5 DEG C; Distil for the second time 7 hours, temperature rise to 25 DEG C, vacuum-drying, to constant weight, to obtain final product, and through proton nmr spectra, carbon-13 nmr spectra, differential thermal analysis TG-DTA collection of illustrative plates, shows that products therefrom is Compound D one Trometamol and hydrate thereof.
Optionally, by above-mentioned Compound D one Trometamol and the further recrystallization of hydrate thereof, with purifying, the solvent of recrystallization can be selected isopropanol-water mixing solutions, acetone-water mixing solutions, alcohol-water mixing solutions, methanol-water mixing solutions or ether-water mixed solution.
Compound D one Trometamol of above-mentioned preparation or its hydrate, through proton nmr spectra, carbon spectrum analysis, are all consistent with embodiment 4.
The lyophilized injectable powder of embodiment 6. Compound D two Trometamols
Compound D two Trometamol 30g (when Compound D two Trometamol hydrate in Compound D two Trometamols)
N.F,USP MANNITOL 120g
PH buffer reagent is appropriate
Water for injection adds to 2500ml
Compound D two Trometamols, the N.F,USP MANNITOL of getting recipe quantity add 2300ml water for injection and dissolve, regulating pH is 7～8, injects water to 2500ml, with filtering with microporous membrane degerming, under hundred grades of conditions, carry out in sterile filling to 1000 cillin bottle, check after loading amount and add plug, box out, glass bottle is sent into in the freeze drying box of having sterilized, to carry out freeze-drying dry, pre-freeze 5 hours, temperature drops to-35 DEG C, distils for the first time 8 hours, and temperature rise is to-5 DEG C; Distil for the second time 7 hours, temperature rise to 25 DEG C, takes out after vacuum gland or inflated with nitrogen gland, and jewelling lid labeling gets product, and every bottle of freeze-dried powder is containing Compound D two Trometamol 30mg.
The lyophilized injectable powder of embodiment 7. Compound D two Trometamols
Compound D two Trometamol 25g (when Compound D two Trometamol hydrate in Compound D two Trometamols)
Sodium-chlor 18g
Glucose 30g
Calcium Disodium Edetate 0.15g
PH adjusting agent is appropriate
Water for injection adds to 2000ml
Compound D two Trometamols, sodium-chlor, the glucose of getting recipe quantity adds after 1800ml water for injection dissolves and adds Calcium Disodium Edetate dissolving, regulating pH is 8～9, inject water to 2000ml, stir with 0.3% (w/v) needle-use activated carbon, at 45 DEG C, stir 30 minutes, with the de-charcoal of the 0.6 μ m filter membrane through sterilizing, after 0.22 μ m membrane filtration degerming, surveying and adjusting pH is 8～9, filtrate is filling sends into freeze drier freeze-drying in 1000 control cillin bottles, add a cover or inflated with nitrogen after add a cover taking-up, label and get final product, wherein freeze-drying curve is as follows:
| Operation | Temperature rise rate | Temperature (DEG C) | |
| 1 | Pre-freeze | Be refrigerated to-40 DEG C by room temperature | |
| 2 | Insulation | -35℃ | |
| 3 | Vacuumize | -35℃ | |
| 4 | Heat up | 6 DEG C/h | Be warming up to-5 DEG C |
| 5 | Heat up | -5 DEG C are warming up to 0 DEG C | |
| 6 | Heat up | 0 DEG C is warming up to 10 DEG C | |
| 7 | Heat up | 10 DEG C are warming up to 25 DEG C | |
| 8 | Insulation | 25℃ |
The above-mentioned freeze-dried powder making, every bottle is 25mg containing Compound D two Trometamols.
Embodiment 8. presses the method for embodiment 6 or embodiment 7, adjust the recipe quantity of Compound D two Trometamols and/or pharmaceutical carrier (or auxiliary material), be prepared into the lyophilized injectable powder that every bottle is 5～100mg containing Compound D two Trometamols, being for example prepared into every bottle is the lyophilized injectable powder of 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg or 100mg containing Compound D two Trometamols.
The injection of embodiment 9. Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate
By the Compound D tromethamine salt described in any one in embodiment 1～5, its hydrate or its solvate, select conventional pharmaceutical excipient, mix with pharmaceutical excipient, press the preparation method of injection, be prepared into freeze-dried powder injection or injection liquid, the Compound D tromethamine salt that every bottle of freeze-dried powder injection or injection liquid contain 0.1～500mg.
The tablets/capsules agent of embodiment 10. Compound D two Trometamols, Compound D one Trometamol, its hydrate or its solvate
By the Compound D tromethamine salt described in any one in embodiment 1～5, its hydrate or its solvate, select conventional pharmaceutical excipient, mix with pharmaceutical excipient, press the preparation method of tablet or capsule, be prepared into tablet or capsule, the Compound D tromethamine salt that every tablet or capsule contain 0.1～500mg.
Embodiment 11., in 1 liter of deionized water, mixes the Trometamol of 0.1mol Compound D and 0.2mol, obtains settled solution, after filtration, is spin-dried for Rotary Evaporators, obtains containing Compound D and Trometamol pharmaceutical composition.
Embodiment 12., in 1 liter of deionized water, mixes the Trometamol of 0.1mol Compound D and 0.1mol, obtains settled solution, after filtration, is spin-dried for Rotary Evaporators, obtains containing Compound D and Trometamol pharmaceutical composition.
The sour reversible reduction experiment of embodiment 13.
Get respectively Compound D two Trometamols, Compound D one Trometamol, its hydrate or the each about 0.1g of its solvate prepared by above-described embodiment, be dissolved in 25ml distilled water, dripping hydrochloric acid tune pH is 1 left and right, all have Precipitation, collect, analyze, consistent with the spectrogram of Compound D, confirm as Compound D, illustrate that the tromethamine salt of the compounds of this invention D has only changed the pharmaceutical property of Compound D, instead of change its pharmacological action.
Embodiment 14.
Compound D tromethamine salt and preparation thereof that embodiment 1 to embodiment 10 is prepared, application in the following areas:
Application in preparation treatment Acute ischemic stroke medicine;
Application in the brain injury causing in preparation treatment cardiac operation under direct vision and the medicine of traumatic brain injury;
Application in the medicine of preparation treatment DPN disease;
Application in the medicine of preparation treatment Parkinson's disease and alzheimer's disease.
Claims (7)
1. the compound shown in formula I:
Wherein n=2 or 1.
2. the preparation method of compound claimed in claim 1, it is included in room temperature to the reflux temperature condition of solvent, be that 1: 1～1.1 Compound D contacts in solvent with Trometamol by mol ratio, reaction salify, and under room temperature or the condition lower than room temperature, make institute's salify crystallization, filter, dry, obtain, wherein said solvent is selected from ethanol, methyl alcohol, Virahol, acetone, acetonitrile, ethyl acetate, water, N,N-DIMETHYLACETAMIDE, the mixing of one or more solvents in dimethyl formamide, optionally can be by reducing Tc or/and steam except partial solvent is to accelerate the formation of crystallization, or the Compound D that is 1: 1 by mol ratio and Trometamol make them dissolve completely in 5～80 DEG C in suitable quantity of water, to stir, lyophilize, to obtain final product,
Wherein, the structural formula of described Compound D is as follows:
3. the preparation method of compound claimed in claim 1, it is included in room temperature to the reflux temperature condition of solvent, be that 1: 2～2.2 Compound D contacts in solvent with Trometamol by mol ratio, reaction salify, and under room temperature or the condition lower than room temperature, make institute's salify crystallization, filter, dry, obtain, wherein said solvent is selected from ethanol, methyl alcohol, Virahol, acetone, acetonitrile, ethyl acetate, water, N,N-DIMETHYLACETAMIDE, the mixing of one or more solvents in dimethyl formamide, optionally can be by reducing Tc or/and steam except partial solvent is to accelerate the formation of crystallization, or the Compound D that is 1: 2 by mol ratio and Trometamol make them dissolve completely in 5～80 DEG C in suitable quantity of water, to stir, lyophilize, to obtain final product,
Wherein, the structural formula of described Compound D is as follows:
4. a pharmaceutical composition, contains any compound claimed in claim 1 and pharmaceutically acceptable carrier.
5. a pharmaceutical composition, contains any compound claimed in claim 1 and pharmaceutically acceptable carrier, and wherein the content of any compound claimed in claim 1 is 0.1～500mg.
6. the preparation method of the pharmaceutical composition described in claim 4 or 5, comprises Compound D one Trometamol, Compound D two Trometamols and pharmaceutically acceptable carrier is fully mixed and made into acceptable any pharmaceutical dosage form in pharmaceutics,
Wherein, the structural formula of described Compound D is as follows:
7. compound claimed in claim 1 application in the following areas: the application in preparation treatment Acute ischemic stroke medicine; Application in the brain injury causing in preparation treatment cardiac operation under direct vision and the medicine of traumatic brain injury; Application in the medicine of preparation treatment DPN disease; Application in the medicine of preparation treatment Parkinson's disease and alzheimer's disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010571246.6A CN102093234B (en) | 2009-11-26 | 2010-11-24 | Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910224894.1 | 2009-11-26 | ||
| CN200910224894 | 2009-11-26 | ||
| CN201010571246.6A CN102093234B (en) | 2009-11-26 | 2010-11-24 | Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102093234A CN102093234A (en) | 2011-06-15 |
| CN102093234B true CN102093234B (en) | 2014-06-18 |
Family
ID=44085940
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010571076.1A Expired - Fee Related CN102079717B (en) | 2009-11-26 | 2010-11-24 | Arginine salt compound of dibasic ester acids and preparation method and medicinal application thereof |
| CN2010105709656A Pending CN102126973A (en) | 2009-11-26 | 2010-11-24 | Meglumine compound of dibasic ester acid and preparation method and medicinal application thereof |
| CN201010571246.6A Expired - Fee Related CN102093234B (en) | 2009-11-26 | 2010-11-24 | Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof |
| CN201010570080.6A Expired - Fee Related CN102079715B (en) | 2009-11-26 | 2010-11-24 | Lysine salt compound of binary ester acid, preparation method and medicinal application |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010571076.1A Expired - Fee Related CN102079717B (en) | 2009-11-26 | 2010-11-24 | Arginine salt compound of dibasic ester acids and preparation method and medicinal application thereof |
| CN2010105709656A Pending CN102126973A (en) | 2009-11-26 | 2010-11-24 | Meglumine compound of dibasic ester acid and preparation method and medicinal application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010570080.6A Expired - Fee Related CN102079715B (en) | 2009-11-26 | 2010-11-24 | Lysine salt compound of binary ester acid, preparation method and medicinal application |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN102079717B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103373957A (en) * | 2012-04-12 | 2013-10-30 | 成都苑东药业有限公司 | Chelate with functions of protecting nerve cells |
| KR102200892B1 (en) * | 2019-05-13 | 2021-01-12 | 대원제약주식회사 | Novel salts of pelubiprofen, preparation method thereof and pharmaceutical compositions comprising thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999016741A2 (en) * | 1997-09-28 | 1999-04-08 | D-Pharm Limited | Lipophilic diesters of chelating agents |
| CN1944378A (en) * | 2006-10-23 | 2007-04-11 | 广东中科药物研究有限公司 | Biphenyl ammonia acetate butantriol salt and its preparing method |
| CN101514189A (en) * | 2008-02-18 | 2009-08-26 | 杨喜鸿 | Glycin diazole tromethamine compound as well as preparation method and medicament application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899275B (en) * | 2005-07-11 | 2013-11-27 | 南京中敬医药科技研究所 | Use of composition of rheinic acid or rheinic acid compounds in preparing medicine for treating osteoarthritis |
| CN1923798A (en) * | 2005-08-30 | 2007-03-07 | 陈亦林 | Preparation method of dexibuprofen amino acid salt and application |
| CN101486644B (en) * | 2009-02-24 | 2012-07-25 | 合肥工业大学 | Preparation of arginine acetylsalicylate |
-
2010
- 2010-11-24 CN CN201010571076.1A patent/CN102079717B/en not_active Expired - Fee Related
- 2010-11-24 CN CN2010105709656A patent/CN102126973A/en active Pending
- 2010-11-24 CN CN201010571246.6A patent/CN102093234B/en not_active Expired - Fee Related
- 2010-11-24 CN CN201010570080.6A patent/CN102079715B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999016741A2 (en) * | 1997-09-28 | 1999-04-08 | D-Pharm Limited | Lipophilic diesters of chelating agents |
| CN1944378A (en) * | 2006-10-23 | 2007-04-11 | 广东中科药物研究有限公司 | Biphenyl ammonia acetate butantriol salt and its preparing method |
| CN101514189A (en) * | 2008-02-18 | 2009-08-26 | 杨喜鸿 | Glycin diazole tromethamine compound as well as preparation method and medicament application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102079715B (en) | 2014-07-23 |
| CN102126973A (en) | 2011-07-20 |
| CN102079717A (en) | 2011-06-01 |
| CN102079715A (en) | 2011-06-01 |
| CN102093234A (en) | 2011-06-15 |
| CN102079717B (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101636152B (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
| JP5235416B2 (en) | Tetracycline metal complexes in solid dosage forms. | |
| CN101633662A (en) | Prasugrel pharmaceutical acid addition salt as well as preparation method and pharmaceutical application thereof | |
| CN101585859B (en) | Novel scutellarin derivative as well as preparation method and pharmaceutical composition thereof | |
| CN108938626B (en) | Carbazochrome sodium sulfonate pharmaceutical composition with good stability and high safety as well as preparation method and application thereof | |
| CN101412690A (en) | Medicinal acid addition salt of silodosin, and preparation and medicament use thereof | |
| CN101712692A (en) | Medicinal acid addition salt of tenofovir disoproxil fumarate and preparation method and medicinal application thereof | |
| CN103087042B (en) | Salts of sitafloxacin and pharmaceutical purposes thereof | |
| ES2742106T3 (en) | New form of solvated rifaximin crystal, production, compositions and uses thereof | |
| CN101541302A (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
| CN100584835C (en) | Novel medicinal salt for cinepazide and preparation method thereof | |
| CN103788043A (en) | Crystal form IV of nicousamide compound as well as preparation method, drug composition and application thereof | |
| CN102093234B (en) | Tromethamine salt compound of dibasic ester acid, preparation method and medicinal application thereof | |
| CN101597271A (en) | The derivative of Ailamode, its preparation method and medicinal application | |
| CN103172576B (en) | The malate acid addition salt of Gefitinib and Synthesis and applications thereof | |
| CN115124532B (en) | Rhein and matrine eutectic crystal, preparation method, composition and application thereof | |
| CN111825547B (en) | Salt of aryl propionic acid compound and pharmaceutical application thereof | |
| CN102442942A (en) | Polymorphic substances of 4-aminopyridine, and preparation and application thereof | |
| CN103214459B (en) | Pantoprazole sodium crystalline compound, pharmaceutical composition and preparation method thereof | |
| CN101514189B (en) | Glycin diazole tromethamine compound as well as preparation method and medicament application thereof | |
| CN104739776A (en) | Solid dispersion composition of levocarnitine as well as preparation method and medical application of solid dispersion composition | |
| CN112778363A (en) | Nitro imidazole azole derivative, preparation method and application thereof | |
| CN102796156B (en) | Adenosine cyclophosphate double-molecule meglumine compound and preparation method thereof | |
| CN112778369B (en) | Triazole derivative and preparation method and application thereof | |
| WO2020056974A1 (en) | Posaconazole phosphate ester mono choline salt, preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: FUZHOU QIANZHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO HAIJING Effective date: 20140505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 234000 SUZHOU, ANHUI PROVINCE TO: 350008 FUZHOU, FUJIAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140505 Address after: Cangshan District of Fuzhou City, Fujian province 350008 Pu Industrial Zone on the Lane Road No. 6 two floor Applicant after: Fuzhou Qianzheng Pharmaceutical Co., Ltd. Address before: 234000, No. 10, building 126, Town God's Temple, Anhui, Suzhou Applicant before: Zhao Haijing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN KANGCHEN RUIXIN PHARMACEUTICAL GROUP CO., Free format text: FORMER OWNER: FUZHOU QIANZHENG PHARMACEUTICAL CO., LTD. Effective date: 20141029 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 350008 FUZHOU, FUJIAN PROVINCE TO: 300051 HEPING, TIANJIN |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141029 Address after: Centertown VIP Plaza, No. 37 Xikang Road Heping District Tianjin 300051 210-2-2 room Patentee after: Tianjin Kangchen Ruixin Pharmaceutical Group Co., Ltd. Address before: Cangshan District of Fuzhou City, Fujian province 350008 Pu Industrial Zone on the Lane Road No. 6 two floor Patentee before: Fuzhou Qianzheng Pharmaceutical Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161009 Address after: 300073 Tianjin city Nankai District Wande Street No. 138 A District Patentee after: Sinopharm holding (Tianjin) health Consultants Limited Address before: Centertown VIP Plaza, No. 37 Xikang Road Heping District Tianjin 300051 210-2-2 room Patentee before: Tianjin Kangchen Ruixin Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 Termination date: 20201124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |